Microvascular repair following a modified crush-avulsion injury in a rat model: effect of recombinant human tissue-type plasminogen activator on the patency rate.
The failure rate of replantations following a crush-avulsion type injury is high. This study has been designed to reproduce an effective standardized crush-avulsion injury model to the femoral artery of the rat and evaluate the antithrombotic efficacy of systemic intravenous administration of recombinant human tissue-type plasminogen activator (rt-PA). The crush-avulsion injury was reproduced by using a bulldog clamp and two hemostats and followed by microvascular repair. The animals were divided into three groups of 20 rats each and received either normal saline, heparin 100 U/kg body weight, or rt-PA 3.5 mg/kg body weight intravenously. Patency tests were performed 20 min and 48 h after blood flow reestablishment. Results showed that this experimental crush-avulsion injury model ensures low patency in the control group, whereas systemic rt-PA administration improves the patency rate statistically significantly compared to control and heparin groups at both 20 min and 48 h postrevascularization.
Lykoudis
E G
EG
Department of Plastic Surgery, Microsurgery and Burns Center, General State Hospital of Athens "G. Gennimatas", Athens, Greece.
Panayotou
P N
PN
Stamatopoulos
C N
CN
Frangia
K B
KB
Papalois
A E
AE
Ioannovich
J D
JD
D000818:Animals; D004195:Disease Models, Animal; D005069:Evaluation Studies as Topic; D005263:Femoral Artery / Q000293:injuries; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008866:Microsurgery; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*; D014654:Vascular Patency / Q000187:drug effects*; D014656:Vascular Surgical Procedures
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator